CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
NCT02043665
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
85
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-small Cell Lung Cancer
Bladder Cancer
Interventions
BIOLOGICAL:
CVA21/pembrolizumab
Sponsor
Viralytics
Collaborators
[object Object]